Resistance to Zidovudine develops due to
**Core Concept**
The development of resistance to Zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI), is a significant clinical concern in the management of HIV infection. This resistance arises due to mutations in the HIV-1 reverse transcriptase gene, which alters the enzyme's ability to bind and phosphorylate the drug.
**Why the Correct Answer is Right**
Zidovudine is phosphorylated by cellular enzymes to its active form, which then competes with the viral reverse transcriptase for dNTPs. The most common mutation associated with zidovudine resistance is the M41L substitution, which reduces the enzyme's affinity for the drug. Another mutation, D67N, also contributes to resistance by altering the enzyme's catalytic site. These mutations can occur spontaneously or under the selective pressure of zidovudine therapy.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is not provided, so we'll proceed to the remaining choices.
**Option B:** While mutations in the HIV-1 reverse transcriptase gene are indeed responsible for zidovudine resistance, this option is incomplete and does not specify the correct mutations.
**Option C:** This option is incorrect because it does not accurately describe the mechanism of zidovudine resistance. **Option D:** This option is also incorrect as it is not a known mechanism of zidovudine resistance.
**Clinical Pearl / High-Yield Fact**
The development of zidovudine resistance can be mitigated by using combination antiretroviral therapy (cART), which reduces the selective pressure on individual drugs and slows the emergence of resistance. Regular monitoring of HIV viral load and resistance testing can also help guide treatment decisions.
**Correct Answer:** M41L substitution is a key mechanism of zidovudine resistance.